OncLive SOSS

Authors

Barbara Pistilli, MD

Latest:

Dr Pistilli on Understanding Dynamic HER2 Expression in Metastatic Breast Cancer

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

Bhuvaneswari Ramaswamy, MD

Latest:

Dr. Ramaswamy on the Real-World Data Implications of Palbociclib in HR-Positive Breast Cancer

Bhuvaneswari Ramaswamy, MD, discusses the importance of real-world data when considering the efficacy of the CDK 4/6 inhibitor palbociclib in hormone receptor–positive breast cancer.

Susan Tsai, MD, MHS

Latest:

Dr. Tsai on Ongoing Research Efforts in Pancreatic Cancer

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer.

Carolina Bernabe, MD

Latest:

Survey Aims to Identify COVID-19–Related Health Care Challenges in Latin America

Outbreaks of coronavirus disease 2019 are on the rise in Latin America, with more than 4 million confirmed cases. In response to this health crisis, elective medical procedures, including cancer screening and care, as well as treatment for conditions beyond the virus, have been held.

Latest:

Wrapping up the Pivotal Highlights From SABCS 2024 With Drs Bora Lim and Stephanie Graff

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Loretta J. Nastoupil, MD

Latest:

Dr Nastoupil on the Background of the TRANSCEND FL Trial in Follicular Lymphoma

Loretta J. Nastoupil, MD, discusses the rationale for launching the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma, highlighting the background for investigating this treatment approach.

David H. Harpole Jr, MD

Latest:

Test for Summarization

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Vamsidhar Velcheti, MD, NYU Langone Health

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Angela Jia, MD, PhD

Latest:

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Latest:

Dr Park on the Assessment of Robot-Assisted Nipple Sparing Mastectomy in Breast Cancer

Ko Un “Clara” Park, MD discusses the assessment of robot-assisted nipple sparing mastectomy in breast cancer.

Stephanie Berg, DO

Latest:

Selecting Optimal Therapy for Advanced Non-Clear Cell RCC

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Solange Peters, MD, PhD, Lausanne University Hospital

Latest:

EGFR+ NSCLC: Advice for Community Oncologists

A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.

Misty D. Shields, MD, PhD

Latest:

Patient Conversations and Considerations in the Extensive-Stage Relapse Setting

Panelists emphasized that clear, compassionate, and ongoing communication with patients diagnosed with small cell lung cancer is vital to support informed decision-making amid evolving treatment options, highlighting the importance of maintaining a broad therapeutic arsenal, integrating multidisciplinary and palliative care early, and regularly reassessing goals to optimize quality of life and treatment outcomes throughout the often prolonged disease course.

Atrium Health Wake Forest Baptist

Latest:

Scientists Create Nanoparticle That Helps Fight Solid Tumors

Researchers from Wake Forest University School of Medicine have discovered a possible new approach in treating solid tumors through the creation of a novel nanoparticle.

Sponsored Content by Ipsen

Yeong “Christopher” Choi, PhD, MBA

Yeong “Christopher” Choi, PhD, MBA, is senior vice president of Industry Partnerships, an associate professor of oncology in the Department of Medicine, and the technical director of the GMP Facility in the Center of Immunotherapy at Roswell Park Comprehensive Cancer Center

Latest:

Dr Choi on the Importance of Education on CAR T-Cell Therapy Manufacturing in Hematologic Malignancies

Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.

Julien Maziéres, MD, PhD

Latest:

Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.

Meera Mohan, MD, MS, FACP

Latest:

Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple Myeloma

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Vania Hungria, MD, PhD

Latest:

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Dr. Vania Hungria presents the Phase 3 DREAMM-7 trial results, demonstrating that belantamab mafodotin, bortezomib, and dexamethasone (BVd) achieved a statistically significant and clinically meaningful overall survival benefit over daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma, with deep, durable responses and manageable safety outcomes.

Laura J Chambers, DO

Latest:

Dr Chambers on the Importance of Patient Counseling in Ovarian Cancer

Laura J. Chambers, DO, discusses the importance of treatment counseling for patients with ovarian cancer considering PARP inhibitor therapy.

x